AUC significantly greater for predicting FMP within next 24 months with AMH- versus FSH-based models
WEDNESDAY, Jan. 22, 2020 (HealthDay News) — Measurement of anti-Müllerian hormone (AMH) levels in blood can help predict the time to final menstrual period (FMP), according to a study published online Jan. 22 in the Journal of Clinical Endocrinology & Metabolism.
Joel S. Finkelstein, M.D., from Massachusetts General Hospital in Boston, and colleagues conducted a longitudinal cohort study to examine the ability of AMH measurement to predict the time to FMP. AMH and FMP were measured in 1,537 premenopausal or early perimenopausal women (mean age, 47.5 years at baseline) and then every 12 months until amenorrhea. AMH was measured with a two-site enzyme-linked immunosorbent assay with a 1.85-pg/mL detection limit.
The researchers found a significantly greater area under the receiver operating characteristic curve for predicting FMP within the next 24 months for AMH- versus follicle stimulating hormone-based models. The probability that a woman with an AMH <10 pg/mL would undergo her FMP within 12 months varied from 51 to 79 percent at <48 years to ≥51 years. For a woman with AMH >100 pg/mL, the probability of not undergoing FMP within the next 12 months varied from 90 to 97 percent in women ≥51 years and <48 years, respectively.
“Ultrasensitive measurements of AMH provide a reliable index of ovarian aging that should prove useful in both clinical and research settings,” the authors write.
Two authors disclosed financial ties to the biotechnology industry.
Copyright © 2020 HealthDay. All rights reserved.
